Lucid Diagnostics/$LUCD
1D1W1MYTD1Y5YMAX
Capital at risk
About Lucid Diagnostics
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
- Ticker
- $LUCD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- New York, United States
- Website
- www.luciddx.com
LUCD Metrics
BasicAdvanced
$149M
-
-$0.46
1.08
-
Price and volume
Market cap
$149M
Beta
1.08
52-week high
$1.63
52-week low
$0.77
Average daily volume
953K
Financial strength
Current ratio
1.331
Quick ratio
1.292
Long term debt to equity
0.046
Total debt to equity
2.28
Interest coverage (TTM)
-2,815.72%
Profitability
EBITDA (TTM)
-49.808
Gross margin (TTM)
-21.69%
Net profit margin (TTM)
-959.76%
Operating margin (TTM)
-930.82%
Management effectiveness
Return on assets (TTM)
-81.62%
Return on equity (TTM)
-556.27%
Valuation
Price to revenue (TTM)
20.241
Price to book
13.66
Price to tangible book (TTM)
13.79
Price to free cash flow (TTM)
-2.336
Free cash flow yield (TTM)
-42.81%
Free cash flow per share (TTM)
-0.335
Growth
Revenue change (TTM)
24.89%
Earnings per share change (TTM)
-52.90%
3-year revenue growth (CAGR)
90.07%
3-year earnings per share growth (CAGR)
-31.77%
What the Analysts think about LUCD
Analyst ratings (Buy, Hold, Sell) for Lucid Diagnostics stock.
Analyst projections of the future price of Lucid Diagnostics stock.
LUCD Financial Performance
Revenues and expenses
LUCD Earnings Performance
Company profitability
Upcoming events
No upcoming events
LUCD News
AllArticlesVideos
Funds containing LUCD
Fund name | Fund size | $LUCD weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.